The prevalence of primary angle closure glaucoma in European derived populations

A systematic review

Alexander C. Day, Gianluca Baio, Gus Gazzard, Catey Bunce, Augusto Azuara-Blanco, Beatriz Munoz, David S Friedman, Paul J. Foster

Research output: Contribution to journalArticle

Abstract

Aim: To estimate the prevalence of primary angle closure glaucoma (PACG) in European derived populations. Method: Systematic review and modelling of PACG prevalence data from population studies. PACG was defined according to the ISGEO definition requiring structural and/or functional evidence of glaucomatous optic neuropathy. Prevalence estimates were applied to the 2010 United Nations projected population figures to estimate case numbers. Results: The prevalence of PACG in those 40 years or more is 0.4% (95% CI 0.3% to 0.5%). Age-specific prevalence values are 0.02% (CI 0.00 to 0.08) for those 40-49 years, 0.60% (0.27 to 1.00) for those 50-59 years, 0.20% (0.06 to 0.42) for those 60-69 years and 0.94% (0.63 to 1.35) for those 70 years and older. Three-quarters of all cases occur in female subjects (3.25 female to 1 male; CI 1.76 to 5.94). Conclusion: This analysis provides a current evidence-based estimate of PACG prevalence in European derived populations and suggests there are 130 000 people in the UK, 1.60 million people in Europe and 581 000 people in the USA with PACG today. Accounting for ageing population structures, cases are predicted to increase by 19% in the UK, 9% in Europe and 18% in the USA within the next decade. PACG is more common than previously thought, and all primary glaucoma cases should be considered to be PACG until the anterior chamber angle is shown to be open on gonioscopy.

Original languageEnglish (US)
Pages (from-to)1162-1167
Number of pages6
JournalBritish Journal of Ophthalmology
Volume96
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Angle Closure Glaucoma
Population
Gonioscopy
Optic Nerve Diseases
United Nations
Anterior Chamber
Glaucoma

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

The prevalence of primary angle closure glaucoma in European derived populations : A systematic review. / Day, Alexander C.; Baio, Gianluca; Gazzard, Gus; Bunce, Catey; Azuara-Blanco, Augusto; Munoz, Beatriz; Friedman, David S; Foster, Paul J.

In: British Journal of Ophthalmology, Vol. 96, No. 9, 09.2012, p. 1162-1167.

Research output: Contribution to journalArticle

Day, Alexander C. ; Baio, Gianluca ; Gazzard, Gus ; Bunce, Catey ; Azuara-Blanco, Augusto ; Munoz, Beatriz ; Friedman, David S ; Foster, Paul J. / The prevalence of primary angle closure glaucoma in European derived populations : A systematic review. In: British Journal of Ophthalmology. 2012 ; Vol. 96, No. 9. pp. 1162-1167.
@article{e5ad7c3f746941de9e343ee2dc606fcf,
title = "The prevalence of primary angle closure glaucoma in European derived populations: A systematic review",
abstract = "Aim: To estimate the prevalence of primary angle closure glaucoma (PACG) in European derived populations. Method: Systematic review and modelling of PACG prevalence data from population studies. PACG was defined according to the ISGEO definition requiring structural and/or functional evidence of glaucomatous optic neuropathy. Prevalence estimates were applied to the 2010 United Nations projected population figures to estimate case numbers. Results: The prevalence of PACG in those 40 years or more is 0.4{\%} (95{\%} CI 0.3{\%} to 0.5{\%}). Age-specific prevalence values are 0.02{\%} (CI 0.00 to 0.08) for those 40-49 years, 0.60{\%} (0.27 to 1.00) for those 50-59 years, 0.20{\%} (0.06 to 0.42) for those 60-69 years and 0.94{\%} (0.63 to 1.35) for those 70 years and older. Three-quarters of all cases occur in female subjects (3.25 female to 1 male; CI 1.76 to 5.94). Conclusion: This analysis provides a current evidence-based estimate of PACG prevalence in European derived populations and suggests there are 130 000 people in the UK, 1.60 million people in Europe and 581 000 people in the USA with PACG today. Accounting for ageing population structures, cases are predicted to increase by 19{\%} in the UK, 9{\%} in Europe and 18{\%} in the USA within the next decade. PACG is more common than previously thought, and all primary glaucoma cases should be considered to be PACG until the anterior chamber angle is shown to be open on gonioscopy.",
author = "Day, {Alexander C.} and Gianluca Baio and Gus Gazzard and Catey Bunce and Augusto Azuara-Blanco and Beatriz Munoz and Friedman, {David S} and Foster, {Paul J.}",
year = "2012",
month = "9",
doi = "10.1136/bjophthalmol-2011-301189",
language = "English (US)",
volume = "96",
pages = "1162--1167",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - The prevalence of primary angle closure glaucoma in European derived populations

T2 - A systematic review

AU - Day, Alexander C.

AU - Baio, Gianluca

AU - Gazzard, Gus

AU - Bunce, Catey

AU - Azuara-Blanco, Augusto

AU - Munoz, Beatriz

AU - Friedman, David S

AU - Foster, Paul J.

PY - 2012/9

Y1 - 2012/9

N2 - Aim: To estimate the prevalence of primary angle closure glaucoma (PACG) in European derived populations. Method: Systematic review and modelling of PACG prevalence data from population studies. PACG was defined according to the ISGEO definition requiring structural and/or functional evidence of glaucomatous optic neuropathy. Prevalence estimates were applied to the 2010 United Nations projected population figures to estimate case numbers. Results: The prevalence of PACG in those 40 years or more is 0.4% (95% CI 0.3% to 0.5%). Age-specific prevalence values are 0.02% (CI 0.00 to 0.08) for those 40-49 years, 0.60% (0.27 to 1.00) for those 50-59 years, 0.20% (0.06 to 0.42) for those 60-69 years and 0.94% (0.63 to 1.35) for those 70 years and older. Three-quarters of all cases occur in female subjects (3.25 female to 1 male; CI 1.76 to 5.94). Conclusion: This analysis provides a current evidence-based estimate of PACG prevalence in European derived populations and suggests there are 130 000 people in the UK, 1.60 million people in Europe and 581 000 people in the USA with PACG today. Accounting for ageing population structures, cases are predicted to increase by 19% in the UK, 9% in Europe and 18% in the USA within the next decade. PACG is more common than previously thought, and all primary glaucoma cases should be considered to be PACG until the anterior chamber angle is shown to be open on gonioscopy.

AB - Aim: To estimate the prevalence of primary angle closure glaucoma (PACG) in European derived populations. Method: Systematic review and modelling of PACG prevalence data from population studies. PACG was defined according to the ISGEO definition requiring structural and/or functional evidence of glaucomatous optic neuropathy. Prevalence estimates were applied to the 2010 United Nations projected population figures to estimate case numbers. Results: The prevalence of PACG in those 40 years or more is 0.4% (95% CI 0.3% to 0.5%). Age-specific prevalence values are 0.02% (CI 0.00 to 0.08) for those 40-49 years, 0.60% (0.27 to 1.00) for those 50-59 years, 0.20% (0.06 to 0.42) for those 60-69 years and 0.94% (0.63 to 1.35) for those 70 years and older. Three-quarters of all cases occur in female subjects (3.25 female to 1 male; CI 1.76 to 5.94). Conclusion: This analysis provides a current evidence-based estimate of PACG prevalence in European derived populations and suggests there are 130 000 people in the UK, 1.60 million people in Europe and 581 000 people in the USA with PACG today. Accounting for ageing population structures, cases are predicted to increase by 19% in the UK, 9% in Europe and 18% in the USA within the next decade. PACG is more common than previously thought, and all primary glaucoma cases should be considered to be PACG until the anterior chamber angle is shown to be open on gonioscopy.

UR - http://www.scopus.com/inward/record.url?scp=84866065195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866065195&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2011-301189

DO - 10.1136/bjophthalmol-2011-301189

M3 - Article

VL - 96

SP - 1162

EP - 1167

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 9

ER -